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ABSTRACT  
Despite recent progress in understanding the cancer genome, there is still a relative delay in 
understanding the full aspects of the glycome and glycoproteome of cancer. Glycobiology has been 
instrumental in relevant discoveries in various biological and medical fields, and has contributed to 
the deciphering of several human diseases. Glycans are involved in fundamental molecular and cell 
biology processes occurring in cancer, such as cell signalling and communication, tumour cell 
dissociation and invasion, cell–matrix interactions, tumour angiogenesis, immune modulation and 
metastasis formation. The roles of glycans in cancer have been highlighted by the fact that 
alterations in glycosylation regulate the development and progression of cancer, serving as 
important biomarkers and providing a set of specific targets for therapeutic intervention. This 
Review discusses the role of glycans in fundamental mechanisms controlling cancer development 
and progression, and their applications in oncology. 
INTRODUCTION  
In recent years, glycobiology has gained increased importance in cancer research, given its role in 
understanding various cancer mechanisms and as it provides a set of targets for diagnostic 
application and therapeutic strategies1–6. Glycosylation can act as a key regulatory mechanism 
controlling several physiopathological processes. Defects in glycosylation in humans and their links 
to disease have shown that the mammalian glycome contains a remarkable amount of biological 
information7. Glycan diversity arises from differences in monosaccharide composition (for example, 
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galactose (Gal) or N‑ acetylgalactosamine (GalNAc)), in link‑  age between monosaccharides (for 
example, between carbons 1 and 3 or carbons 1 and 4), in anomeric state, in branching structures, in 
other substitutions (such as sulfation state) and in linkage to their aglycone part (protein or lipid)8,9 
(FIG. 1). Characterizing the biological functions of each glycan10, as well as those of glycan‑binding 
proteins (including galectins and sialic acid-binding immunoglobulin-type lectins (siglecs)), has been 
shown to make important contributions to the cancer field1–3,5. Different types of glyco‑  
conjugates interfere with key cancer cell processes as well as with the tumour microenvironment, 
leading to cancer progression. This Review describes how glycans affect and regulate the genesis 
and progression of cancer. The recent cutting‑ edge technological developments in glycobiology 
and their innovative applications in the oncology field are also introduced and discussed. 
Glycoconjugates and glycosylation 
Glycosylation is defined as the enzymatic process that produces glycosidic linkages of saccharides 
to other saccharides, proteins or lipids1,11. Glycoconjugates are primarily defined according to the 
nature of and linkage to their aglycone (non‑glycosyl) part (FIG. 1). Glycoproteins carry one or 
more glycans covalently attached to a polypeptide backbone, usually via nitro‑  gen or oxygen 
linkages, in which case they are known as N-glycans or O-glycans, respectively8,12,13 (FIG. 2). A 
common type of protein O‑glycosylation is ini‑  tiated via GalNAc — the first monosaccharide that 
connects serine or threonine in particular forms of protein O‑glycosylation (O‑GalNAc) called 
mucin‑  type O-glycosylation12,13 — which can be extended into various different structures14. 
There are other types of O-glycans as well, such as those attached via O-mannose, and the 
nucleocytoplasmic glycan O‑ linked β‑N‑ acetylglucosamine (O-GlcNAc)15 (FIGS 1,2). In addition, 
other forms of glycosylation exist that occur only in specific types of proteins, such as the Notch 
receptor, and these have been shown to be impor‑  tant in cancer cell biology16 (BOX 1). Moreover, 
several proteins are linked to the cell membrane through a glycosylphosphatidylinositol (GPI) 
anchor; these are known as GPI‑ anchored proteins8 (BOX 2). Other major classes of 
glycoconjugates include the proteoglycans and glycosphingolipids (FIG. 1). Proteoglycans are 
glycoconjugates that have one or more glycosaminoglycan (GAG), such as chondroitin sulfate, 
heparan sulfate and keratan sulfate8. Hyaluronan is a GAG primarily found as a free sugar chain. 
Glycosphingolipids are molecules composed of a glycan linked to a lipid ceramide. The structural 
and functional classifications of glycosphingolipids have traditionally been based on their glycan 
part8. The first sugars linked to ceramide in higher animals are typi‑  cally β‑ linked galactose 
(galactosylceramide) or glucose (glucosylceramide). In vertebrate glycosphingolipids, the glucose 
moiety is typically substituted with β‑ linked galactose, creating a lactosylceramide 
(d‑galactosyl‑ 1,4‑β‑d‑  glucosylceramide). Glycosphingolipids include a series of neutral ‘core’ 
structures and gangliosides, which typically carry one or several sialic acids and have been shown to 
regulate receptor tyrosine kinase (RTK) signalling17. 
Glycosylation alterations in cancer 
Changes in glycosylation associated with oncogenic transformation were first described over more 
than six decades ago18,19. Those observations were further corroborated with the advent of 
monoclonal antibody technology, which showed that tumour‑ specific antibodies were directed 
against carbohydrate epitopes and, in most cases, were oncofetal antigens present on tumour  
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 glycoproteins and glycosphingolipids20,21. Tumour cells display a wide range of glycosyla‑  tion 
alterations compared with their non‑ transformed counterparts. Protein glycosylation increases 
molecular hetero geneity as well as the functional diversity within cell populations (FIG. 2). This 
heterogeneity occurs because aberrant glycan modifications are protein‑  specific, site‑ specific 
(different sites on a given protein can be differentially glycosylated) and cell‑ specific. The 
specificities of glycosylation depend on various intrinsic factors of the glycosylation process within a 
given cell or tissue type. Two principal mechanisms underlying the tumour‑ associated alterations 
of carbo‑  hydrate structures were first postulated by Hakomori and Kannagi, in the so‑ called 
incomplete synthesis and neo‑ synthesis processes22. The incomplete syn‑  thesis process, 
occurring more often in early stages of cancer, is a consequence of the impairment of the nor‑  mal 
synthesis of complex glycans expressed in normal epithelial cells, which leads to the biosynthesis of 
trun‑  cated structures, as seen with sialyl Tn (STn) expression in gastrointestinal and breast 
cancers23,24. Conversely, neo‑ synthesis, commonly observed in advanced stages of cancer, refers 
to the cancer‑ associated induction of certain genes involved in the expression of carbohydrate 
determinants, as seen in the de novo expression of cer‑  tain antigens (such as sialyl Lewis a (SLea) 
and SLex) in many cancers25. In general, a shift from the normal glycosylation pathway occurs in 
cancer cells, leading to altered glycans expression owing to one or various factors. First, altered 
expression of glycans can be attributed to under‑  or overexpression of glycosyltransferases (owing 
to dys‑  regulation at the transcriptional level25–28, dysregulation of chaperone function29,30 
and/or altered glycosidase activity31). Second, altered glycan expression can be due to changes in 
the tertiary conformation of the peptide backbone and that of the nascent glycan chain. Third, the 
differences can stem from the variability of vari‑  ous acceptor substrates as well as the availability 
and abundance of the sugar nucleotide donors and cofac‑  tors32. Finally, changes in glycan 
expression can be due to the expression and localization of the relevant glycosyltransferases in the 
Golgi apparatus33,34. Mislocalization and/or changes in the activity of the glycosyltransferases 
results in the synthesis of imma‑  ture core glycan structures35,36. Studies have shown that early 
acting enzymes synthesizing core O‑glycans, such as GalNAc transferases, core 1 GalNAc β1,3‑ ga 
lactosyltransferase 1 (C1GalT1) and core 2 β1,6‑N‑  acetylglucosaminyltransferase (C2GnT), are 
enriched in cis- and medial‑Golgi cisternae34,37, whereas late‑  acting enzymes (such as 
sialyltransferases) are enriched in trans-Golgi cisternae. In cells, overexpression of α‑GalNAc 
α‑ 2,6‑ sialyltransferase I (ST6GalNAc‑ I; encoded by ST6GALNAC1), the enzyme responsible for 
STn biosynthesis23,24,38, leads to expression of enzymes in all Golgi cisternae and disrupts 
glycosylation by pre‑  maturely adding sialic acid to form the STn antigen36,38. The most‑widely 
occurring cancer‑ associated changes in glycosylation are sialylation, fucosylation, O‑glycan 
truncation, and N- and O‑ linked glycan branching2,39,40 (FIGS 2,3).  
Sialylation. Sialylation is an important modification in cellular glycosylation, as sialylated 
carbohydrates have an important role in cellular recognition, cell adhesion and cell signalling. An 
increase in global sialylation — especially in α2,6‑  and α2,3‑ linked sialylation — owing to altered 
glycosyltransferases expression has been closely associated with cancer41. The lactosaminic chains 
are frequently terminated with a sialic acid. For example, α2,6‑ sialylated lactosa‑  mine 
(Sia6LacNAc) is the product of β‑galactoside α2,6‑ sialyltransferase I (ST6Gal‑ I)42, an enzyme 
with altered expression in various malignancies — includ‑  ing colon, stomach and ovarian cancer42 
— and that has been reported to be a predictive marker of poor progno‑  sis in colon cancer43. 
Other major sialylated antigens associated with cancer are SLea and SLex (REF. 2) (FIG. 2). SLea 
and SLex have been demonstrated to be highly expressed in many malignant cancers, and SLex 
expression levels have been correlated with poor survival in cancer patients44,45. SLex is the 
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well‑ known ligand for selectins46, which are vascular cell adhesion molecules that belong to a 
family of C‑ type lectins (which require calcium for binding). During inflammation, selectins 
mediate the initial attach‑  ment of leukocytes to the endothelium during the process of leukocyte 
extravasation46. In cancer, SLex interactions with selectins regulate the metastatic cascade by 
forming emboli of cancer cells and platelets and favouring their arrest on endothelia (FIG. 4), 
therefore determining the malignant behaviour and development of metastasis47. Tumour 
metastasis has been shown to be attenuated in animal models by the use of specific GAGs, such as 
heparin, that inhibit P‑ selectin‑mediated interactions of platelets with carcinoma cell‑ surface 
ligands48. The SLea tetrasaccharide, which is detected by the serological assay CA19‑9, is a 
cancer‑ associated marker widely used in the clinical practice. The CA19‑9 assay has been mostly 
applied in patients with an established diagnosis of pancreatic, colorectal, gastric or biliary can‑  cer 
and used to monitor clinical response to therapy3,49. In addition, elevated preoperative 
concentrations of CA19‑9 have been shown to be associated with poor prognosis in colon and 
gastric carcinoma50. Increased sialylation in cancer also includes the expression of polysialic acid, 
which is associated with several types of cancers and is frequently expressed in high‑grade 
tumours51,52. Polysialic acid can often be pre‑  sent in neural cell adhesion molecule 1 (NCAM1), 
and this is associated with aggressiveness and poor clinical outcome in cancers, including lung 
cancer, neuroblastoma and gliomas51,52. Gangliosides are also overexpressed in tumours such as 
melanoma, neuroblastoma and breast cancer, in which they mediate cell proliferation, tumour 
growth and cancer cell migration17,53. 
Box 1 | The unique type of Notch glycosylation  
Notch signalling is essential for cell fate, and dysregulation of the pathway leads to various human 
diseases, including cancer96. Glycosylation of the Notch extracellular domain has been shown to 
regulate Notch activity96. The Notch ligands (the Delta, Serrate and LAG-2 family of proteins) bind 
to the extracellular domain of Notch receptor, triggering its activation by inducing a conformational 
change that exposes cleavage sites in Notch. Cleavage at these sites results in liberation of the 
Notch intracellular domain, which translocates to the nucleus and controls the transcriptional 
activation of the transcription factor recombining binding protein suppressor of hairless (RBP-Jκ). 
The Notch extracellular domain is modified with different types of carbohydrates, including Asp-
linked N-glycans and several O-glycans, such as O-fucose208. O-fucose monosaccharides are 
elongated to a N-acetylglucosamine β1-3fucose (GlcNAcβ1-3Fuc) disaccharide by the action of the 
Fringe N-acetylglucosaminyltransferase in Drosophila melanogaster and by the Fringe homologues 
in vertebrates96,209. The disaccharide can be further elongated to the tetrasaccharide 
Neu5Acα2-3/6Galβ1-4GlcNAcβ1-3Fuc by the sequential action of several glycosyltransferases in 
mammals96.  
Fringe was demonstrated to be a modulator of Notch activity209. Three Fringe homologues exist in 
mammals: lunatic fringe, manic fringe and radical fringe210. Notch regulation by glycosylation, 
such as the addition of GlcNAc by Fringe, was shown to interfere with Notch–ligand interactions, 
promoting Notch–Delta binding and reducing Notch–Serrate binding96,209.  
Several studies have reviewed the mechanisms of glycosylation in the regulation of this important 
receptor in cancer96. Glycosylation-dependent modulation of Notch signalling controls 
development, maintains tumour cell ‘stemness’ and mediates cancer metastasis96. 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
Fucosylation. Fucosylation has been also associated with cancer. Fucosylated glycans are 
synthesized by a range of fucosyltransferases (Fuc‑Ts; Fuc‑TI–Fuc‑TXI (encoded by FUT1–FUT11, 
where FUT3 is also known as the Lewis gene, Le)), with fucosylation existing as a non‑ extendable 
modification and being generally sub‑  divided into terminal fucosylation (giving rise to spe‑  cific 
Lewis blood‑group antigens, such as Lex and Ley and Lea and Leb) and core fucosylation54. The 
ter‑  minal steps of the biosynthesis of SLe antigens include the α1,3‑  or α1,4‑ fucosylation of a 
previously α2,3‑ sialylated type 1 (SLea) or type 2 (SLex) chains54,55 (FIG. 2). The enhanced 
expression of SLex in adult T cell leukaemia cells has been shown to be dependent on Fuc‑TVII 
activity. The aetiologic agent of this leukaemia, the human T‑ lymphotropic virus 1 (HTLV‑ 1) 
retrovirus, encodes a transcriptional activator protein, TAX, which regulates the FUT7 gene 
encoding Fuc‑  TVII, the limiting enzyme controlling SLex synthesis in leukocytes56. In breast 
tumours, the expression of SLex seems to be regulated mainly by Fuc‑TVI (encoded by FUT6)57. 
However, the biosynthesis of SLe antigens in gastro‑  intestinal cancer may depend on the 
coordinated expres‑  sion of several glycosyltransferases. The expression of both SLex and SLea 
antigens expressed by glycolipids in colon cancer tissues has been related to the activation of a 
β1,3GlcNAc transferase; this enzyme synthesizes a sugar chain that is a precursor for both type 1 
and 2 Lewis structures58. A similar mechanism was observed in gastritis induced by Helicobacter 
pylori59,60, a bacterium that expresses adhesins that recognize glycan receptors expressed by the 
gastric epithelium subsequently causing gastric ulcers and, potentially, gastric carcino genesis5 
(BOX 3). Fuc‑TVI has also been reported as a major enzyme modulating the SLex biosynthesis in 
colorectal cancer (CRC)61. Core fucosylation consists in the addition of α1,6‑ fucose to the 
innermost GlcNAc residue  of N‑glycans through the action of Fuc‑TVIII (encoded by FUT8) 
(FIG. 2). Overexpression of FUT8 and core fucosylation is an important feature in several cancers, 
such as lung cancer and breast cancer62,63. This increased core fucosylation is reflected in the 
serum levels during the process of hepatocarcinogenesis64. Interestingly, core fucosylation of 
α‑ fetoprotein is an approved biomarker for the early detection of hepa‑  tocellular carcinoma 
(HCC), distinguishing it from chronic hepatitis and liver cirrhosis65. In breast cancer, increased core 
fucosylation of epidermal growth factor receptor (EGFR) was associated with increased 
dimerization and phosphorylation, which resulted in increased EGFR‑mediated signalling 
associated with tumour cell growth and malignancy62,66.  
Branching and bisecting GlcNAc N‑ glycans. During malignant transformation, a frequently 
occurring glycosylation change in cancer cells is the increased expression of complex 
β1,6‑branched N‑ linked glycans2,67 (FIGS 2,3). Increased GlcNAc‑branching N‑glycan 
expression is due to increased activity of GnT‑V, which is encoded by the mannoside acetyl‑  
glucosaminyltransferase 5 (MGAT5) gene. MGAT5 expression is regulated by the RAS–RAF–MAPK 
sig‑  nalling pathway, which is activated in cancer67. Branched N‑glycans are further modified by 
β1,4‑GalTs and elongated with poly‑N‑ acetyllactosamine (repeats of Galβ1,4GlcNAcβ1,3) by 
β1,3‑GnTs, and further capped with sialic acid and fucose. This poly‑N‑ acetyllactosamine 
structure is a ligand for galectins, a family of con‑  served carbohydrate‑binding proteins, which 
form galectin–glycan structures termed ‘lattices’ (REF. 68). Galectins have important roles in 
cancer, contribut‑  ing to neoplastic transformation, tumour cell survival, angiogenesis and tumour 
metastasis69. Overexpression of MGAT5 in an immortalized lung epithelial cell line resulted in loss 
of contact inhibition, increased cell motility and tumour formation in athymic mice70, as well as in 
enhanced invasion and metastasis in mouse mammary carcinoma cells71. Moreover, early events in 
breast carcinoma formation in a Her2‑ transgenic mouse mammary tumour model were found to 
be regulated by GnT‑V72. In addition, downregulation of GnT‑V in mouse mammary cancer cell 
 Version: Postprint (identical content as published paper) This is a self-archived document from i3S – Instituto de 
Investigação e Inovação em Saúde in the University of Porto Open Repository For Open Access to more of our 
publications, please visit http://repositorio-aberto.up.pt/  
 
A
0
1
/0
0
 
lines resulted in a significant suppression of tumour growth and metastasis71. Breast cancer 
progression and metastasis induced by a viral oncogene in transgenic mice is markedly sup‑  
pressed in Mgat5-deficient background73. Moreover, GnT‑V‑mediated glycosylation regulates the 
colon cancer stem cell compartment and tumour progression through WNT signalling74. In contrast 
to the function of GnT‑V, GnT‑ III (encoded by MGAT3) catalyses the addition of bisect‑  ing 
GlcNAc N‑glycans in a β1,4‑ linkage, suppressing additional processing and elongation of N-
glycans such as the β1,6‑branching structures. GnT‑ III coun‑  teracts the role of GnT‑V in cancer, 
being involved in the suppression of cancer metastasis75. MGAT3 trans‑  fection into mouse 
melanoma B16 cells with high metas tatic potential resulted in a significant reduction of 
β1,6GlcNAc branching (owing to GnT‑ III and GnT‑V enzymatic competition), leading to a 
significant sup‑  pression of lung metastasis in mice. GnT‑ III suppresses tumour metastasis through 
the regulation of key glyco‑  proteins, such as EGFR, integrins and cadherins66,76, as 
described below. 
Truncated O‑glycans. Another common feature of tumours is the overexpression of truncated 
O‑glycans (FIGS 2,3). The GalNAc‑ type O‑glycans, also called mucin‑  type O‑glycans, are 
frequently found in most transmem‑  brane and secreted glycoproteins. During malignancy, 
aberrant glycosylation also occurs in glycoproteins that display abnormal expression of shortened 
or truncated glycans, such as the disaccharide Thomsen–Friedenreich antigen (T antigen, also 
known as core 1) and the mono‑  saccharide GalNAc (also known as Tn) and their sia‑  lylated forms 
(ST and STn (Neu5Acα2‑ 6GalNAcα‑O‑R), respectively), which result from the incomplete 
synthesis of O‑glycans77. Altered expression of polypeptide GalNAc trans‑  ferases (ppGalNAcTs) 
— the enzymes initiating the mucin‑ type O‑glycosylation12,13 — is often observed in cancer78,79. 
The ppGalNAcTs control the sites and density of O‑glycan occupancy12,13, and changes in their 
expression lead to alterations in O‑glycosylation80. In addition, enzymes competing for the same 
substrate can also induce expression of truncated glycans and exposure of protein epitopes that 
would other‑  wise be hidden in the normally glycosylated protein. The relative enzymatic activities 
of C2GnT and α2,3‑ sialyltransferase I (ST3Gal‑ I) have been shown to determine the O‑glycan 
structure in cancer cells81. These relative activities underlie the aberrant expres‑  sion of a 
tumour‑ associated epitopes on glycoproteins, such as mucins in breast81 and gastric82 cancers. 
STn is rarely expressed in normal healthy tissues but can be detected in most carcinomas, such as 
those from the pancreas83,84, stomach23,85,86, colorectum23,87, breast38, bladder88 and 
ovary89, correlating with decreased cancer cell adhesion, increased tumour growth, increased 
tumour cell migration, invasion and poor prognosis. The abnormal synthesis of STn in cancer occurs 
owing to the overexpression of ST6GalNAc‑ I. Mutations in T‑ synthase C1GalT1‑ specific chap‑  
erone 1 (C1GALT1C1) — which blocks further O‑glycan elongation and shifts the pathway towards 
generation of Tn — can also lead to STn expres sion through the action of ST6GalNAc‑ I90,91 
(FIG. 2). 
Therefore, STn has been proposed as an important prognostic marker and a target for the design of  
anticancer vaccines92,93. 
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Box 2 | GPI-anchored proteins and disease  
Glycosylphosphatidylinositol (GPI)-anchored proteins are formed by a glycan bridge between 
phosphatidylinositol and a phosphoethanolamine, which is then linked to the carboxy-terminal 
amino acid of a protein. This structure typically constitutes the only anchor to the lipid bilayer 
membrane for some proteins8. Mutation in the GPI phosphatidylinositol 
N-acetylglucosaminyltransferase subunit A (PIGA) gene leads to defects in the synthesis of the GPI 
anchor, resulting in deficiency of all GPI-bound proteins. Haematopoietic stem cells that are 
defective in GPI anchor assembly owing to a mutation in the PIGA gene preferentially expand in the 
bone marrow and give rise to defective peripheral blood elements that are deficient in GPI-
anchored protein expression. Mutation in the X-linked PIGA gene causes paroxysmal nocturnal 
haemoglobinuria, a disease characterized by haemolytic anaemia, thrombosis and impaired bone 
marrow function, with an increased risk of developing leukaemia211. 
 
Glycosylation in the cancer cell 
Glycans have been found to participate in numerous fun‑  damental biological processes involved in 
cancer, such as inflammation (BOX 3), immune surveillance, cell–cell adhesion76,94,95, cell–matrix 
interaction76, inter‑  and intracellular signalling96–99, and cellular metabolism100,101 (FIG. 4). 
Furthermore, glycans alter protein conformation and structure, thereby modulating the functional 
activity of the protein102. Unravelling the biological significance of glycan‑based interactions in 
cancer can contribute to the deciphering of molecular mechanisms underlying  the biology 
of cancer. 
Glycosylation in tumour cell–cell adhesion. The devel‑  opment of malignant tumours is in part 
characterized by the ability of a tumour cell to overcome cell–cell adhesion and to invade 
surrounding tissue. Epithelial cadherin (E‑ cadherin) is a transmembrane glycopro‑  tein103 and a 
major epithelial cell–cell adhesion mole‑  cule in cancer104. Glycans can have a profound effect on 
tumour cell–cell adhesion by directly interfering with E‑ cadherin functions. GnT‑V overexpression 
in gastric cancer cells induces E‑ cadherin cellular mislocalization from the cell membrane into the 
cytoplasm and its functional impairment94,95. The addition of GnT‑V‑mediated 
β1,6GlcNAc‑branched N‑glycans to E‑ cadherin leads to incorrectly assembled and 
non‑ functional adherens junctions, which compromise cell–cell adhesion94,95,105 and 
downstream signalling pathways106, contributing to tumour invasiveness and metastases107. 
Preventing this aberrant glycosylation in a specific Asp site improves E‑ cadherin functions in 
cancer108. Interestingly, patients with gastric carcinoma displaying loss of E‑ cadherin function (not 
explained at the genetic or structural level) exhibit an increase in β1,6GlcNAc‑branched N‑glycans 
on E‑ cadherin5,94. Conversely, GnT‑ III‑mediated bisecting GlcNAc N‑glycans counteract GnT‑V 
activity through E‑ cadherin regulation75,94. This E‑ cadherin glycan modification was associated 
with a delayed turnover rate at cell membrane94,109, inhibition of endocytosis94, decreased 
phosphorylation of β‑ catenin that remained in complex with E‑ cadherin110, and increased 
stability of adherens junctions, promoting tumour suppression5,94,95. Moreover, expression of 
GnT‑ III is also associated with suppression of epithelial‑ to‑mesenchymal transition28,111. 
Therefore, a mutual regulatory mechanism between E‑ cadherin‑mediated cell–cell adhesion and 
its glycosylation exists in cancer, which is controlled by the competitive action of GnT‑ III and 
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GnT‑V, and can culminate in either tumour suppression or tumour metastasis, respectively5,112 
(FIG. 4). Cancer cells produce increased levels of sialylated glycans, leading to the high expression of 
tumour‑  associated antigens2,113. Increased expression of sialylated antigens promotes cell 
detachment from the tumour mass through electrostatic repulsion of nega‑  tive charges, which 
physically inhibits and disrupts cell–cell adhesion114,115. Transfection of breast cancer cells with 
ST6Gal‑ I results in increased cell migra‑  tion and decreased cell–cell adhesion in vitro116 (FIG. 4). 
Furthermore, sialylated glycans (such as SLex) can pro‑  mote the adhesion of tumour cells to 
vascular endothe‑  lial cells through their interaction with selectins, such as E‑ selectin, mediating 
the initial steps of the forma‑  tion of cancer metastases2 (FIG. 4). In addition, de novo expression of 
STn in gastric carcinoma cells modulates the malignant phenotype, inducing more‑ aggressive cell 
behaviour, with decreased cell–cell aggregation and increased matrix interaction, migration and 
invasion85. RNA interference‑mediated gene silencing of ST6GALNAC1 suppresses the metastatic 
potential of gastric cancer cells owing to a reduction in expression of insulin growth factor I (IGF‑ I) 
and reduced activa‑  tion of signal transducer and activator of transcription, STAT5B 117. 
Furthermore, somatic mutations and hyper‑  methylation of C1GALT1C1 have shown that loss of 
C1GALT1C1 function leads to STn expression, preventing cell–cell interactions and contact 
inhibition of cell growth in cancer cells84. Clinically, increased sialylation is often associated with 
invasiveness and poor prognosis of cancer patients44,47. 
Glycosylation in cell–matrix interaction and signalling. The extracellular matrix (ECM) is composed of 
a dynamic and complex array of glycoproteins, collagens, GAGs and proteoglycans. It provides 
mechanical and structural sup‑  port, as well as spatial context, for signalling events, with direct 
implications in tumour development, maintenance of stem cell niches and cancer progression118. 
Heparan sulfate proteoglycans (HSPGs) are present on the cell surface and in the ECM and can 
modulate cell growth and differentiation, controlling embryogenesis, angiogenesis and 
homeostasis. HSPGs contain one or more covalently attached heparan sulfate GAG chains119. 
There are different groups of HSPGs classified according to their location: membrane HSPGs, such 
as syndecans and the GPI‑ anchored proteoglycans, the glypicans; the ECM HSPGs, such as agrin, 
perlecan and type XVIII collagen; and the secretory‑ vesicle HSPG, serglycin119. HSPGs can bind 
cytokines, chemokines and growth factors, protecting them against proteolysis; in addition, HSPGs 
can act as co‑ receptors for various growth factors for tyrosine kinase receptors, lowering their 
activation thresholds or changing the duration of their signalling reactions119 (FIG. 4). 
Overexpression of proteoglycans occurs in several cancers in which the heparan sulfate chains 
covalently bound to the proteoglycans can modulate the activation of protein receptors, such as 
HER2, EGFR, MET (also known as hepatocyte growth factor receptor (HGFR)) and transforming 
growth factor‑β (TGFβ)120. Heparan sulfate chains regulate the interactions121, and increase the 
solubility, of various signalling molecules122, therefore increasing their access to receptors and 
facilitating signal transduction. For instance, heparan sulfate chains can release HGF, inducing cell 
growth and motility through interaction with MET121, which is frequently activated in cancer 
cells99 (FIG. 4). Heparan sulfate chains can also release vascular endothelial growth factor A 
(VEGFA), a regulator of angiogenesis that stimulates growth, motility, and tubulogenesis in 
vascular endothelial cells through interactions with VEGF receptor 1 (VEGFR1) and VEGFR2 
(REF. 121). Another important membrane receptor involved in matrix‑dependent cell motility and 
migration is CD44, which is the main receptor for hyaluronic acid. CD44 is a multifunctional cell 
surface molecule involved in can‑  cer cell proliferation, differentiation, migration and sig‑  
nalling123. CD44 splicing variants have been associated with tumour development and 
progression124. The role of CD44 glycosylation in matrix‑dependent cell adhe‑  sion, motility and 
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migration is far from being elucidated. Nevertheless, evidence has shown that changes in glyco‑  
sylation of CD44 can markedly influence hyaluronic acid ligand recognition and binding, modifying 
cancer cell signalling125. Treatments of CD44 with inhibitors of glycosylation and de‑glycosylating 
enzymes signifi‑  cantly change the binding to hyaluronic acid, modulating CD44‑dependent 
signalling and function126. Moreover, glycosylation modification of CD44 induced by transfection 
of α1,2–Fuc‑T enhanced cell motility and tumori‑  genicity in rat carcinoma cells127. Additionally, 
GAG forms of CD44 containing chondroitin and heparin sul‑  fate chains modulate the binding of 
tumour cells to fibro‑  nectin128. Proteoglycans are also involved in the biogenesis and recognition 
of exosomes, which are secreted vesicles of endosomal origin involved in signalling processes129. 
Syndecans control the interaction with key acces‑  sory components of the endosomal‑ sorting 
complexes required for transport machinery. In addition, hepara‑  nase modulates 
syndecan‑ controlled pathways, foster‑  ing endosomal membrane budding and the biogenesis of 
exosomes by trimming the heparan sulfate chains on syndecans and controlling the selection of 
specific cargo to exosomes129. Hyaluronidases also have many roles in cancer metastasis by 
participating in the degradation of the ECM surrounding the tumour, enabling cancer cells to 
disseminate from the primary tumour and allowing invasion by degradation of the basement 
membrane and by clearing the ECM of the secondary site130. Recent studies demonstrated that 
expression of bulky glycoproteins in the cancer cell glycocalyx facilitates integrin clustering by 
funnelling active integrins into adhesions and by applying tension to matrix‑bound integrins, 
independently of actomyosin contractility131. Expression of large tumour‑ associated glycoproteins 
in non‑ transformed cells facilitates integrin‑dependent growth factor signalling to support cell 
survival, further confirming that alterations of glycoprotein expres‑  sion in the cancer cell 
glycocalyx could foster invasion and metastasis by mechanically enhancing cell‑ surface receptor 
function131. Cell–ECM interactions play essential parts during the acquisition of migration and 
invasive behaviour of tumour cells132. Integrins are carriers of N‑glycans and are important 
receptors for signals in the ECM and connect many biological functions, such as cell proliferation, 
protection against apoptosis and malignant transformation131. Integrin expression is upregulated 
in migratory cells associated with tumour metastases133. N‑glycans on α5β1 integrin, a receptor 
for fibronectin (encoded by FN1), are required for αβ‑heterodimer formation and for proper 
integrin–matrix inter action76. Changes in N‑glycans in cancer can regulate integrins functions. 
Transformation of NIH3T3 cells with an oncogenic RAS gene resulted in enhancement of cell 
spreading on fibronectin due to increased modifica‑  tion of α5β1 integrins with 
β1,6GlcNAc‑branching N‑glycans134 through the upregulation of the  
 RAS–RAF–MAPK signalling pathway and subsequent activation of MGAT5 transcription. Similarly, 
over‑  expression of human fibrosarcoma cells with GnT‑V resulted in an increased cell migration 
towards fibro‑  nectin and invasion through the Matrigel due to an increase in β1,6‑branching 
N‑glycans on α5β1 integrin135. Moreover, the characterization of carbohydrate moieties of 
α3β1 integrin, the receptor for laminin‑ 5 showed that β1,6GlcNAc‑branched structures were 
highly expressed in metastatic human melanoma cells136. Changes in N‑ linked β1,6‑branching 
occurring dur‑  ing oncogenesis alter cell–matrix adhesion and migration by inhibiting the clustering 
of integrins and subsequent signal transduction pathways136. In contrast to the over‑  expression of 
GnT‑V, the overexpression of GnT‑ III resulted in an inhibition of α5β1 integrin‑mediated cell 
spreading and migration, and the phosphorylation of focal adhesion kinase (FAK). The affinity of 
the binding of α5β1 integrin to fibronectin was greatly reduced as a result of the introduction of a 
bisecting GlcNAc N‑glycans on the α5 subunit137. Similarly, in MKN45 gas‑  tric cancer cells, the 
overexpression of GnT‑ III suppresses α3β1 integrin‑mediated cell migration on laminin‑ 5, 
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counteracting the GnT‑V activity138. Overall, GnT‑ III is described to suppress cancer metastases 
by at least two major mechanisms: an enhancement in cell–cell adhesion and a downregulation of 
cell–ECM adhesion139. Furthermore, an increased terminal α2,6‑ sialylation of integrins N‑glycans 
can control cancer cell migratory and metastatic potential, interfering with the ligand‑  binding 
properties of integrins101,140. Analysis of cancer cells that overexpress ST6Gal1 consistently 
indicates altered adhesion of cells to ECM substrates, such as colla gen, fibronectin and laminin in 
colon cancer141 and breast cancer cell lines116. Additionally, altered N‑glycosylation of integrins 
can have an impact on their cis‑ interaction with membrane‑  associated receptors, including 
EGFR142 and the tetra‑  spanin family of proteins, as well as gangliosides in the microdomain. 
Glycosylation of α3β1 integrin was dem‑  onstrated to regulate its association with the tetra spanin 
CD151, modulating cell spreading and motility143. Therefore, changes in the N‑glycosylation 
profile of integ‑  rins modulate tumour cell motility and migration through interference with the 
supramolecular complex formation (tumour cell focal adhesions) on the cell surface. In the 
formation of these focal adhesions, integrins interact with HSPG on the surface of tumour cells144. 
Syndecan‑4 is frequently upregulated in a range of cancers145; it binds to fibronectin and 
laminin‑ 5 enhancing the function of β1 integrin during cell spreading146. Similarly, syndecan‑ 1 
was described to functionally couple with αvβ3 integrin in breast cancer cells, resulting in increased 
αvβ3‑dependent cell spreading and migration147.  
Box 3 | Glycosylation at the interface of inflammation-induced cancer  
During inflammation, a considerable number of glycosylation changes occur, and some of these 
have been associated with the carcinogenesis process. Helicobacter pylori, a Gram-negative 
bacterium specialized in the colonization of the human stomach, can cause gastric ulcers, and 
persistent infection may cause chronic atrophic gastritis with the development of intestinal 
metaplasia, dysplasia and gastric carcinoma5. The adhesion of H. pylori to the gastric mucosa is 
mediated by different bacterial adhesins that recognize glycans expressed by the gastric mucosa. 
The antigen-binding adhesin BabA binds to fucosylated antigens normally expressed by secretor 
individuals212, and the sialic acid-binding adhesin SabA recognizes sialylated Lewis glycans (sialyl 
Lewis a (SLea) and SLex) expressed in gastritis213. Inflammation-induced glycosylation alterations, 
such as the aberrant overexpression of SLex, occur because of changes in glycosyltransferases 
expression59,60,214. Changes in glycosylation have also been studied in acute-phase proteins, such 
as α1 antitrypsin, as potential biomarkers in cancer and in acute and chronic inflammatory 
conditions215. Furthermore, glycosylation alterations have been shown to correlate with disease 
severity in certain inflammatory conditions, such as in inflammatory bowel disease216. In addition, 
glycosylation alterations have been reported in circulating proteins produced by the liver in patients 
with inflammatory diseases, such as gastritis203 and pancreatitis215.  
Several studies have shown that the sialic acid N-glycolylneuraminic acid (Neu5Gc) is enriched in 
red meat, an epidemiological risk factor for cancer development217. Humans cannot synthesize 
Neu5Gc because the human gene cytidine monophosphate-N-acetylneuraminic acid hydroxylase 
(CMAH), which encodes the enzyme responsible for the synthesis of CMP-Neu5Gc from 
CMP-N-acetylneuraminic (CMP-Neu5Ac) acid is irreversibly mutated. The active form of CMAH is 
found in apes218, and the mutated CMAH form is estimated to have originated 2–3 million years 
ago, prior to the emergence of the genus Homo218. Neu5Gc has been shown to be bioavailable, 
undergoing metabolic incorporation into human tissues. Human-like Neu5Gc-deficient mice have 
been shown to develop inflammatory conditions when fed with Neu5Gc and challenged with 
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Neu5Gc-specific antibodies. Such mice developed hepatocellular carcinomas217. These studies 
demonstrate the potential role in cancer development of the sialic acid Neu5Gc and provide an 
explanation for the epidemiological association between red meat consumption, inflammation and 
cancer risk. 
Glycosylation in cancer metabolism and signalling. A key feature of cancer cell metabolism is a shift 
from oxidative phosphorylation to aerobic glycolysis (the Warburg effect)148, which is 
characterized by high rates of glucose uptake to cope with the increased energetic and biosynthetic 
needs to generate a tumour. Additionally, to help meet increased biosynthetic demands, cancer 
cells also upregulate glutamine uptake. The abundance of glucose in the cytoplasm of cancer cells 
not only contributes to increased glycolysis but also increases flux into the metabolic branch 
pathways, such as the hexo samine biosynthetic pathway (HBP). Approximately 3–5% of the total 
glucose entering a cell is shunted through this pathway149. Therefore, increased glucose and 
glutamine uptake by cancer cells probably drives increased HBP flux. The end‑product of HBP is 
uridine diphosphate (UDP)‑GlcNAc, which is a critical metabolite that is subsequently used for O-
GlcNAcylation as well as for  O- and N‑glycosylation150. Given O‑GlcNAcylation responsiveness 
to the glucose flux, O‑GlcNAc can act as a ‘nutritional sensor’ (REF. 151). Increased levels of 
O‑GlcNAc transferase (OGT) have been found in breast cancer, and knockdown of OGT in vitro 
reduces cancer hyper‑O‑GlcNAcylation and inhibits tumour growth, invasion and metastasis, 
further indicating that elevated O‑GlcNAc contributes to cancer progression152–154. Moreover, 
O‑GlcNAc modulates key protein functions by regulating protein phosphorylation, altering protein 
degradation, controlling protein localization and mediating transcription155. O‑GlcNAc modi‑  
fications have been implicated in key molecular events occurring in cancer, such as tumour cell 
proliferation (by regulating the activities of transcription factor forkhead box protein M1(FoxM1) 
and cyclin D1, which are both involved in cell cycle progression154), cancer cell survival and 
angiogenesis (through the effect of hyper‑O‑Glc‑  NAcylation (via activation of nuclear 
factor κB‑mediated signalling153) and upregulation of VEGFA and matrix metalloproteinases 
(MMPs)156, respectively), and cancer cell invasion and metastasis (through O‑GlcNAc  regulation 
of E‑ cadherin trafficking and function)157. Many oncogene and tumour‑ suppressor gene products 
were shown to be modified by O‑GlcNAc158. MYC undergoes O‑GlcNAcylation at Thr58, which is 
also a phosphorylation site. In fact, O‑GlcNAcylation has extensive crosstalk with phosphorylation 
and serves as a nutrient sensor to modulate signalling, transcription and cytoskeletal functions158. 
Altered phosphorylation events affect GlcNAcylation levels and vice versa. Increased MYC 
O‑GlcNAcylation competes with phos‑  phorylation, stabilizing MYC and thus contributing to 
oncogenesis159. This type of interplay also occurs with the p53 tumour‑ suppressor protein160. 
Similarly to O‑GlcNAcylation, N‑glycan branching is nutrient sensitive, with functional 
consequences for the cancer cell. The degree of N‑glycan branching modulates the activity and/or 
signalling and surface retention of many cell surface proteins, including growth factor receptors97. 
Cell surface glycoprotein receptors have different number of N‑glycan sites. The number of 
N‑glycans is defined by the protein sequence of each glycoprotein, and the types of N-glycan 
structures are determined by the Golgi N‑glycan‑processing pathway and metabolite sup‑  ply to 
sugar–nucleotide pools161. Receptors that stimu‑  late cell proliferation, growth and oncogenesis 
(such as EGFR, IGF receptor (IGFR), fibroblast growth factor (FGFR) and platelet‑derived growth 
factor (PDGFR)) have more N‑glycan sites (8–16 Asn‑X‑Ser/Thr sites, in which X is any amino acid) 
per 100 amino acids, and longer extracellular domains. Conversely, growth‑ arrest receptors 
involved in organogenesis and differentiation (such as TGFβ receptor 1 (TGFβR1) and TGFβR2) have 
few N‑glycan sites161. Lau et al. proposed a mechanism for metabolic regulation of cellular 
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transition between cell proliferation and arrest and/or differentiation that arises from the 
cooperation of complex N‑glycan num‑  ber and the degree of branching structures161. Changes in 
metabolic flux through the HBP affect the stability and retention of receptors at the cell surface by 
modulating the interaction of branched N‑glycans with galectin‑ 3 (REFS 162,163). The galectin‑ 3 
lattice restricts receptor endocytosis, enhancing the signalling68,161. Hence, the more N‑glycan 
sites, the more β1,6‑ branching structures are added, which crosslink with galectins, precluding 
endocytosis and thereby increasing signalling161,162. Mammary carcinoma cells derived from 
polyomavirus middle T (PyMT) Mgat5−/−‑ transgenic mice are less responsive to IGF, EGF, PDGF, 
FGF and TGFβ compared with Mgat5+/+ tumour cells, showing reduced galectin‑ 3 binding and 
internalization of receptors from the cell surface to endosomes164. Similarly, human cancer cells 
with targeted silencing of the MGAT5 gene also exhibit reduced EGFR signalling165. Sensitivity to 
EGF and TGFβ cytokines was rescued by hexosamine supplementation with UDP‑GlcNAc or by 
GnT‑V expression, implying that remodelling of N‑glycans in tumour cells is sensitive to 
metabolism161. Accordingly, the decrease of galectin lattice interactions induced by the addition of 
bisecting GlcNAc N‑glycans counterbalances the highly branched N‑glycosylation of EGFR and 
PDGFR, restraining its downstream signalling and in this way retarding mam‑  mary tumour 
progression166. GnT‑ III overexpression reduces the ability of EGF to bind to its receptor, blocking 
EGFR‑mediated ERK phosphorylation and increasing EGFR endocytosis167. Increasing intracellular 
metabolic flux with UDP‑GlcNAc promotes a hyperbolic activation profile for high‑n receptors 
(receptors with a high number of N‑glycan sites (growth receptors)) and a sigmoid or switch‑ like 
profile for low‑n receptors (receptors with a reduced number of N‑glycan sites (arrest receptors)), 
thereby regulating the transition between cell growth and differentiation161. Overall, the nutrient 
flux that regulates complex N‑glycan biosynthesis coordinates the cellular response of tumour cells 
determining growth, invasion and drug sensitivity100. Interestingly, the presence of branching 
N‑glycans on VEGFR2 interacting with galectin‑ 1 underlies an aberrant and compensatory 
angiogenesis mechanism associated with tumour growth in tumours resistant to anti‑VEGF 
treatment69. Gangliosides have been described as important modulators of signal transduction. 
Ectopic expression or inhibition of specific glycosyltransferases modifying gangliosides regulates 
RTK signalling. Within glycolipid‑ enriched microdomains, RTKs can be modulated by glycans, 
resulting in inhibition of ligand‑  induced dimerization and autophosphorylation or in activation of 
receptor signalling without ligand binding. The RTK modulation depends on the glycan structure; 
monosialogangliosides (such as GM3 and GM1) are considered negative regulators of RTKs, 
whereas disialo‑  gangliosides (such as GD2, GD3, GD1a and GD1b) are considered activators of 
RTKs17. Furthermore, physio‑  pathological changes in cell membrane ganglioside com‑  position 
have been shown to result in different cellular responses168. Several growth factor receptors, 
including EGFR, FGFR, PDGF, MET and IGFR, are regulated by gangliosides17,53,169. RTKs are 
located in glycolipid‑  enriched microdomains, and changes in gangliosides modify the molecular 
composition and the structure of glycolipid‑ enriched microdomains, leading to modifi‑  cations in 
the location and organization of RTKs in the cellular membrane and altered activation53,169. 
Further regulation of specific ganglioside GD3 due to formation of 9‑O‑ acetyl GD3 that renders 
GD3 unable to induce apoptosis has been shown in gliomas170. 
Glycans in tumour immune surveillance 
Glycans regulate various aspects of the immune response interfering with tumour editing. Such 
regulation is mediated by various lectins — such as galectins, C‑ type lectins and siglecs — that bind 
glycans and regulate immune processes such as those relevant for pathogen recognition, thereby 
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defining the course of adaptive immune responses171,172. Cancer immune surveillance is an 
important host protection process thought to inhibit carcino‑  genesis and maintain cellular 
homeostasis. Transformed cells can be eliminated by immune effector cells, resulting in immune 
selection of tumour cell variants with decreased immunogenicity and resistance to immune effector 
cells. Glycan‑ specific natural and induced antibodies (such as those against GM2, globo H and Ley) 
can mediate tumour cell killing and tissue destruction by complement‑dependent cytotoxicity173. 
In addition, aberrant O‑glycosylation on the surface of cancer cells can induce 
antibody‑dependent cellular cytotoxicity (ADCC)174 and may interact with dendritic cell‑ specific 
intercellular adhesion molecule‑ 3 grabbing non‑ integrin 1 (DC‑SIGN; also known as CD209)175 
and macrophage galactose‑ type C‑ type lectin176 expressed on denditric cells. Galectins can also 
modulate the immune and inflammatory responses and might have a key role helping tumours to 
escape immune surveillance, therefore having diagnostic and prognostic applications171,177–179. 
Targeting altered glycosylation as an immunothera‑  peutic strategy — for example, with 
anticancer vaccines that target tumour‑ associated carbohydrate antigens180 — provides an 
appealing option for cancer treatment92. Examples include vaccines targeting the mucin‑ related 
Tn, STn, and T antigens for suppression of breast cancer, the gangliosides GM2 and GD3 for 
treatment of mela‑  noma, and the glycosphingolipid globo‑H for prostate cancer treatment181. 
Some of these anticancer vaccines can be designed to incorporate only those elements required for 
a desired immune response182–184. Antibodies targeting GD2 disialo‑  ganglioside have been 
tested in numerous clinical trials in neuroblastoma with impressive antitumour effects and survival 
outcomes185. Passive immunotherapy using antibodies directed to glycoform‑ specific targets 
expressed in tumour cells can be effective at inducing ADCC174. Other studies have shown that 
ADCC is a key mechanism by which some currently used therapeutic antibodies mediate their 
antitumour effects. Variations of glycosylation on the heavy chain of the therapeutic antibodies can 
increase the affinity between the antibody and Fcγ receptor, resulting in increased ADCC186. 
Glycans in cancer diagnosis and treatment 
New approaches for cancer early diagnosis, risk prediction and treatment are urgently needed, and 
glycans can be a source for the development of new non‑ invasive biomarkers. Some of the 
most‑ common clinically utilized sero‑  logical biomarkers for cancer diagnosis and monitoring of 
malignant progression, as well as prognostic biomarkers of disease recurrence, are 
glycoproteins3,49. These include prominent biomarkers that are widely used in patients with 
prostate cancer (prostate‑ specific anti‑  gen (PSA))187, ovarian cancer (carcinoma antigen 125 
(CA125; also known as mucin‑ 16 (MUC16)))188, colon cancer (SLea, CA19‑9, 3,49 and 
carcinoembryonic antigen (CEA)189), breast cancer (aberrantly glycosylated MUC1 (also known as 
CA15‑ 3))190,191 gastric cancer (SLea, CA19‑ 9)3,49 and pancreatic cancer (SLea,, CA19‑9)192 
(TABLE 1). Although all of these serological biomarkers have been shown to have an aberrant glyco 
sylation in cancer193–195, they have limited application owing to their relative low specificity, 
precluding their use for screening strategies and diagnostic potential. The reduced specificity and 
sensitivity of these assays for early detection of cancer has driven a search for novel biomarkers 
based on the detection and measurement of specific glyco‑  forms of a certain protein that could 
contribute to the establishment of a biomarker with higher specificity for early detection of cancer 
or for diagnosis at a precancerous stage. A story of success is that of α‑ fetoprotein (AFP), a 
glyco‑biomarker used for the detection of liver diseases. AFP is a broadly validated protein for 
diagnosis of HCC65; however, serum levels of AFP do not allow dis‑  crimination between HCC and 
the benign liver diseases. Therefore, an additional tumour marker was proposed, based on a 
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glycosylated form of AFP (the AFP‑L3 frac‑  tion) that shows a highly significant increase in the 
fuco‑  sylation index in HCC patients in comparison to chronic liver diseases196. The fucosylated 
AFP‑L3 fraction was approved by FDA as a marker for early detection of HCC that appears in serum 
at the stage of liver cirrhosis, just before the onset of HCC, being therefore considered the best 
approved marker in patients with HCC65,196. Other liver‑ secreted proteins, such as GP73, 
kininogen and haptoglobin, have been shown to be fucosylated, acting as promising biomarkers for 
early detection of HCC and disease progression197. With the advent of new technologies and new 
methods for glycan analysis, many examples of aberrant glycans associated with cancer were 
discovered198. The recent application of precise and stable glycogene editing in mammalian cell 
lines combined with high‑ throughput mass spectrometry approaches has contributed to the 
characterization of the O‑glycoproteome of cancer cells, disclosing new biological information and 
generating putative disease biomarkers199,200. In addition, the newly developed high‑  
throughput platform technologies have further enabled the analysis of large cohorts of samples in 
an efficient manner198,201. An increased concentration of fucosylated haptoglobin occurs in serum 
of patients with pancreatic cancer compared with that of patients with other types of cancer, such 
as gastric cancer or CRC, and healthy controls202. Recently, STn antigen was found in circulating 
CD44 in serum from patients with gastric cancer200. In addition, STn has been found in 
plasminogen in serum from patients with intestinal metaplasia and gastric carcinoma203. 
Additional studies showed altered glycosylation (both fucosylation and sialylation) in PSA as a 
specific biomarker for prostate cancer that is able to distinguish it from benign pros‑  tate 
hyperplasia187,204. Therefore, it is likely that targeting glycans in combination with the protein 
backbone will provide greater diagnostic and prognostic perfor‑  mance, with sufficient sensitivity 
and specificity for clinical applications. Additionally, circulating exosomes enriched in certain 
glycoconjugates have major potential for early detection of cancer. This is the case of proteoglycan 
glypican 1 (GPC1), which has been shown to identify circulating pancreatic cancer exosomes and 
allows the early detection of this cancer205. Serum antibodies against tumour‑ associated glycan 
antigens have been shown to have potential applications as biomarkers for early cancer 
detection206. The detection of aberrant glycosylated MUC1‑ specific autoantibodies correlates 
with CRC, predicting this cancer with 95% specificity207. However, the low sensitivity of the assay 
supports the use of it in combination with other mark‑  ers, suggesting that a combination of 
antibody signa‑  tures may eventually enable a biomarker panel for the early detection of 
cancer207. Furthermore, microarrays of glyco peptides displaying cancer‑ associated glycans open 
new avenues for the expansion of glycoconjugates and glycoforms for further cancer biomarker 
discovery with potential clinical applications206. In summary, the impressive progress in the 
under‑  standing the role of glycans in cancer in the recent years has contributed to the discovery of 
glycans as promising biomarkers, highlighting their application in the clinical setting as appealing 
targets for personalized medicine180. 
Conclusions and perspectives 
Glycosylated proteins and other glycoconjugates are major components of cells, defining and 
modulating several key physiological processes in normal tissues. Genetic, epigenetic, metabolic, 
inflammatory and envi‑  ronmental mechanisms can lead to modifications of glycosylation that 
drive several biological processes in cancer. The understanding of the molecular basis under‑  lying 
these glycan modifications will further contribute to explain cancer cell interactions, extracellular 
com‑  munications (including extracellular vesicles and exo‑  some communication) and cancer 
immunology. The foreseeable new knowledge in the glycobiology field, with the rapid expansion of 
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novel (glyco)engineered cell and model platforms, which are providing increas‑  ing advances in the 
understanding of how glycosylation modulates biological functions, will allow the develop‑  ment of 
a relatively unexploited field of drugs based on inhibitors, glycan antagonists and glycan‑ function 
mod‑  ulators. Furthermore, the combination of an increasing amount of data on glycomics and 
glycoproteomics and the recent advances in genomics, transcriptomics, prot‑  eomics and 
metabolomics will have a major impact on the unravelling of novel targets and strategies for the 
early diagnosis, prognosis, patient stratification and improved treatment of cancer. 
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Figure 1 | Common classes of glycoconjugates in mammalian cells. Glycans can be found in 
various types of macromolecules. Glycosphingolipids are major components of the outer leaflet of 
the cell plasma membrane. These ceramide-linked glycans are made of a variable series of 
structures that can be further modified with terminal sialic acids8,17. Proteins can be glycosylated 
by the covalently attachment of a saccharide to a polypeptide backbone, via N- linkage to Asp or 
O-linkage to Ser/Thr8. Mucin-type O-glycans are frequently found in secreted or membrane-
associated glycoproteins and are initiated by N-acetylgalactosamine (GalNAc) O-linked to 
Ser/Thr13. O-glycans can be extended, producing various ‘cores’ and different terminal structures 
that are usually fucosylated and sialylated14. Other types of O-glycans include the O-mannose 
(O-Man), O-fucose (O-Fuc), O-galactose (O-Gal) and nucleocytoplasmic O-linked 
β-N-acetylglucosamine (O-GlcNAc)11,15. N-glycosylation occurs in the consensus peptide 
sequences Asn-X-Ser/Thr (in which X denotes any amino acid). N-glycans share a common 
pentasaccharide core region (highlighted in the figure as a dotted line box) that can be further 
diversified into oligomannose, hybrid or complex types and further modified by the terminal 
structures GlcNAc, Gal and sialic acid8. Some glycoproteins can also be found in the outer leaflet of 
the plasma membrane linked to a phosphatidylinositol; these are called 
glycosylphosphatidylinositol (GPI)-anchored proteins8. Glycosaminoglycans are linear co-polymers 
of acidic disaccharide repeating units mostly found attached to the so-called proteoglycans8. An 
exception is hyaluronic acid, which is a glycosaminoglycan found free in the extracellular matrix. 
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Figure 2 | Schematic representation of important glycan structures. The figure represents specific 
N-linked (a) and O-linked (b) glycan structures, as well as the terminal Lewis and sialylated Lewis 
structures (c). The key enzymes responsible for the addition of specific sugar residues are also 
shown in blue boxes. Examples include the polypeptide N-acetylgalactosamine transferases 
(ppGalNAc-Ts; a family of 20 enzymes, including GalNAc-T1, GalNAc-T2, GalNAc-T3, GalNAc-T4, 
GalNAc-T5 and GalNAc-T6), sialyltransferases (such as α-galactoside α-2,6-sialyltransferase I 
(ST6Gal-I), α2,3-sialyltransferases (ST3Gal-Ts) and α-GalNAc ST6Gal-I (ST6GalNAc-I)), 
N-acetylglucosamine (GlcNAc) transferases (GnTs; such as GnT-III, GnT-V, core 2 GnTs (C2GnTs) 
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and β3GnT) and fucosyltransferases (Fuc-Ts). The latter include Fuc-TVIII (which mediates the 
addition of ‘core’ α1,6Fuc to N-glycans); Fuc-TI and Fuc-TII, which add fucose (Fuc) in α1,2 linkage to 
galactose (Gal); Fuc-Ts that mediate the addition of Fuc in α1,3 linkage to an α2,3-sialylated type 2 
chain (Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI, Fuc-TVII and Fuc-TIX); and Fuc-Ts that add Fuc in α1,4 
linkage to an α2,3-sialylated type 1 chain (Fuc-TIII and Fuc-TV). The blue boxes highlighted in part c 
show the carbohydrate terminal Lewis antigens. Lewis type 1 antigens includes Lewis a (Lea), Leb 
and sialyl Lewis a (SLea); the type 2 group includes Lex, Ley and SLex. C1GalT1, core 1 GalNAc 
β1,3-GalT 1; GalT, galactosyltransferase; GlcA, glucuronic acid; Man, mannose; STn, sialyl Tn. 
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Figure 3 | Important tumour-associated glycans. Tumour cells often display glycans with different 
structures and levels of expression compared with their normal counterparts. These tumour-specific 
glycans are considered a hallmark of cancer cells. The most-widely occurring changes in 
glycosylation associated with cancer include an increase in overall sialylation2,25. Aberrant 
glycosylation in cancer frequently involves an increase in sialyl Lewis x (SLex) and SLea (REF. 41) 
antigens, as well as an increase in terminal α2,6-sialylated structures, both in truncated O-linked 
glycans (such as sialyl Tn (STn))23,35,38 and in N-linked glycans113, and an increase in the 
α2,8-linked polymer known as polysialic acid52. Moreover, certain sialic acid-containing 
glycosphingolipids called gangliosides (including monosialogangliosides, such as GM3 and GM1a, 
disialogangliosides, such as GD1a, GD2 and GD1b, and trisialogangliosides, such as GT1b) have 
been associated with malignancy17. Another broadly occurring change in glycosylation associated 
with cancer is an enhancement of β1,6-N-acetylglucosamine (β1,6GlcNAc)-branched structures in 
N-linked glycans caused by an increased activity of N-acetylglucosaminyltransferase V (GnT-V)67. 
Overexpression of ‘core’ fucosylation (the addition of α1,6-fucose (α1,6-Fuc) to the innermost 
GlcNAc of N-glycans) by fucosyltransferase VIII (Fuc-TVIII) is also considered an important event in 
tumour development and progression196.Gal, galactose; GalNAc, N-acetylgalactosamine; Man, 
mannose. 
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Figure 4 | Role of glycans in cancer development and progression. Glycans play fundamental 
parts in key pathological steps of tumour development and progression. In the process of tumour 
cell dissociation and invasion, glycans interfere with cell–cell adhesion. The modification of 
epithelial cadherin (E-cadherin) with β1,6-N-acetylglucosamine (β1,6GlcNAc)-branched N-glycan 
structures through enhanced N-acetylglucosaminyltransferase V (GnT-V) activity impairs cell 
adhesion and promotes tumour cell invasion94. These branched structures can be extended and the 
α2,6-sialylated terminal structures interfere with tumour cell adhesion. The presence of E-cadherin 
N-glycans with bisecting GlcNAc structures catalysed by GnT-III leads to protein stability and 
suppression of tumour progression75,94,95. Aberrant O-glycosylation, such as expression of sialyl 
Tn (STn) owing to overexpression of α-N-acetylgalactosamine (α-GalNAc) α-2,6-sialyltransferase I 
(ST6GalNAc-I)36,38 or mutations in C1GalT1-specific chaperone 1 (C1GALT1C1), is also associated 
with tumour cell invasion84,85. The process of tumour growth and proliferation is characterized by 
altered glycosylation of key growth factors receptors, which modulates their activity and 
signalling161. Expression of gangliosides in the cancer cell membrane can also modulate signal 
transduction, activating various cellular pathways that induce tumour growth and progression17. 
Altered O-GlcNAcylation is also associated with cancer progression153. In the process of tumour 
cell migration, integrins show altered glycosylation in both O-linked and N-linked glycans76. 
Terminal sialylation interferes with cell–extracellular matrix (ECM) interactions, promoting an 
increased migratory and invasive phenotype140. The aberrant glycosylation of vascular endothelial 
growth factor receptor (VEGFR) modulates its interaction with galectins and is associated with 
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tumour angiogenesis69. The tumour-associated carbohydrate determinants sialyl Lewis x (SLex) 
and SLea serve as ligands for the adhesion receptors expressed in activated endothelial cells 
(E-selectin), platelets (P-selectin) and leukocytes (L-selectin), promoting cancer cell adhesion and 
metastasis46. Fuc, fucose; Gal, galactose; GlcA, glucuronic acid; Man, mannose; RTK, receptor 
tyrosine kinase; Xyl, xylose. 
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Table 1 | Examples of serological markers with clinical applications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
